Cancer31 non cancer (1243)

Study on Cancer and Non-Cancer Conditions

Enrolling By Invitation
18 years - 82 years
Female
Phase N/A
184 participants needed
1 Location

Brief description of study

500 patients will be prospectively recruited to undergo a fast breast MRI examination. The women will be recruited for the study will meet the following criteria: 1. status post primary breast cancer treated with breast conservation therapy 3 years prior to recruitment 2. negative DBT examination six months prior to recruitment 3. all breast densities 4. clinically asymptomatic - no palpable masses, focalthickening, or clinically significant discharge We will identify these patients EPIC database utilizing the date of their last mammogram. The patients will be sent a letter explaining the study and the opportunity to enroll in the study. Interested patients may contact our research coordinators by the phone number provided in the letter. The study recruitment information will also be shared with referring physicians. Physicians may also directly refer patients to the study.

Detailed description of study

Women treated for primary breast cancer who undergo breast conservation therapy face an increased risk of developing a second breast cancer in the ipsilateral and the contralateral breast. Although mammographic screening is recommended annually, the sensitivity of mammography is limited in these patients due to the post treatment changes from previous surgery and radiation. We propose supplemental screening with an abbreviated form of breast MRI ("fast MRI") examination in addition to mammographic screening, in order to study whether we can detect subclinical disease that may not be detected on mammography or on physical examination. Several tumor characteristics correlate with overall survival such as the extent of local recurrence and the size of the local recurrence, with larger extent and increased size of local recurrence correlating with adverse survival. In addition, the shorter time interval to the ipsilateral breast cancer recurrence from completion of treatment, is associated with increased risk of developing distant metastasis and breast cancer mortality. We will assess additional cancer detection with fast MRI after negative mammography in the ipsilateral as well as the contralateral breast. The goal of the supplemental screening with fast breast MRI would be to detectsubclinical disease not detected on mammography and thus improve patient outcomes.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating
  • Age: 18 years - 82 years
  • Gender: Female

Inclusion Criteria:

  1. Status post primary breast cancer (both invasive and DCIS) treated with breast conservation therapy at least three years prior to recruitment
  2. Negative DBT examination within six months prior to recruitment
  3. All breast densities
  4. Clinically asymptomatic - no palpable masses or focal thickening, etc.

Exclusion Criteria:

  1. Patients who are pregnant or lactating.
  2. Patients who have not had a mammogram (digital breast tomosynthesis) in the past 6 months.
  3. Patients who are unwilling or unable to provide written informed consent.
  4. Patients symptomatic for breast disease (e.g. experiencing discharge, lumps, etc.).
  5. Recent breast surgery in the past two years including breast enhancements (e.g. implants or injections) benign surgical biopsies.
  6. Patients who are unable to receive an MRI with Gadolinium contrast.
  7. Patients who have not had an MRI of the breast within the past year.

This study investigates the effects of an investigational medication on cancer and non-cancer conditions. The purpose is to understand how the treatment affects individuals with these conditions.

The study focuses on evaluating the safety and effectiveness of the investigational medication in participants with different health conditions.

  • Who can participate: Participants must meet specific age criteria and other health-related eligibility factors, which will be provided upon inquiry.
  • Study details: Participants will receive an investigational medication, and their health will be monitored throughout the study.
Updated on 13 Jan 2026. Study ID: 117436
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator